微信直播

Prof. Philip Bonomi:挑战与使命并存

Published at: 2015年第1卷第S1期

ME A
关键词:

 编者按:2017年10月15-18日,第十八届世界肺癌大会(WCLC 2017)成功于日本横滨召开。置身于全球颇负盛名的肺癌和其他胸部恶性肿瘤的多学科肿瘤学顶尖学术会议中,不仅可以获取最新研究成果、最新医疗技术,还可以与来自世界各地的知名专家进行互动交流。这次大会中, AME出版社十分荣幸地采访了来自美国拉什大学医学中心 (Rush University Medical Center) 的Prof. Philip Bonomi

人物聚焦:Philip D. Bonomi

Dr. Philip D. Bonomi currently serves as professor of Medical Oncology and Internal Medicine at the Rush University Medical Center in Chicago. The acclaimed institution has consistently been ranked among the best hospitals in the Unites States and was most recently awarded a top 50 ranking in 11 of 16 care categories.

He completed his medical degree at the University of Illinois College of Medicine at Chicago. He then completed his residency program Geisinger Medical Center in the field of internal medicine. Dr. Bonomi joined Rush University Medical Center by completing a fellowship in medical oncology.

Dr. Bonomi’s primary area of interest is within the field of thoracic and cardiothoracic oncology, with his specialties being in lung cancer and mesothelioma. The majority of Dr. Bonomi’s research interest is in the field of lung cancer treatment and detection. What’s more, he has also authored or co-authored over 150 publications, primarily in the field of small-cell lung cancer detection and survival-rate improvements. He is a member of the International Association for the Study of Lung Cancer. With over three decades of experience in the field of lung cancer research, he has served as the Chairman of the Thoracic Committee for the Eastern Cooperative Oncology Group. His most research has centered on the study of new chemotherapeutic agents for multi-modality therapies in the treatment of small-cell lung cancer.

作为一名享誉全球的肺癌肿瘤学家,尤其在肺上沟瘤的治疗中,Philip Bonomi教授认为,如果肺上沟瘤仅扩散到上沟,并没有到纵隔淋巴结,治愈率是相当高的。标准疗法是术后联合使用顺铂,依托泊苷治疗和放疗,将会有接近50%的治愈机会。唯一不足的是,这类特殊肿瘤的患病群体数目较小,目前还没有随机研究来证明这是最好的治疗方法。其次,鉴于其位置和分期的特殊性,往往很难被诊断出来。大多时候人们会因为肩膀疼痛去看医生,但事实上癌细胞已经在影响你的臂丛,给你带来疼痛。因此,治疗的关键在于早诊断,防止癌细胞扩散到纵膈淋巴结和其他部位。

当谈到肺上沟瘤的未来研究方向,Philip Bonomi教授则认为,未来所有的肿瘤都寄望于通过放疗和化疗来治愈,局部的晚期肺癌则可以采用免疫疗法。根据最近的一项试验PACIFIC (Patients with Stage III Unresectable Non-Small Cell Lung Cancer)表明,假定在有限的时期里,但采取了PD-L1免疫检查点抑制剂的Durvalumab疗法,复发的风险仍降低了50%以上。同样地,我们还需要更多的时间去观察总体生存情况,但这些结果已经是相当鼓舞人心。

早在40年前,无论是临床研究或者基础研究,致力于肺癌研究的人可是相当少。甚至连Philip Bonomi教授的同事也很惊讶他是如何在肺癌研究的这条道路上坚持下来的。他自己则直言,从没把自己当作一名肺癌肿瘤学家,只知道这是挑战和使命并存。因为总有那么一群人急迫需要正确的医学指导和帮助,这一直促使他尽自己所能把眼前工作做好,做精。当看到现在肺癌肿瘤领域后起之秀遍地开花,Philip Bonomi教授则表示心里甚是欣慰。

更多精彩内容,欢迎观看视频。

现场答疑

  1. As a world-recognized leader in the field of lung cancer, especially in the treatment of superior sulcus tumors, what do you think is the best treatment strategy for patient with superior sulcus tumors from your perspective?

  2. Is it possible to perform surgery on patients with superior sulcus tumors in stage IIIA (N2)?

  3. What do you think is the future research direction for superior sulcus tumors?

  4. Along the way to be an excellent researcher, would you like to share with us any stories behind? What encourage you to choose the career/field?


采访编辑:凌    晨 AME Publishing Company

写作编辑:冯雁萍 / Bella Poon AME Publishing Company

特别鸣谢:沈建飞医生对采访问题的指导

comments powered by Disqus

附件